Psilocybin reduces cancer patients' depression, and shows promise for binge eating disorder

Key Findings

🔬 Engineered bacteria now produce 2,000 mg/L of psilocybin

• Scientists achieved 2,000 mg/L psilocybin production using engineered E. coli

• Traditional mushroom extraction yields low concentrations requiring extensive processing, while chemical synthesis remains costly

• Biotechnological approaches using yeast and fungi have also reached over 200 mg/L, establishing microbial platforms as viable for industrial-scale production

🧠 Psilocybin changes how we see the world - literally

• Eye-tracking studies of 23 participants found psilocybin increased fixation on visually salient parts of images and reduced the distance between eye movements

• Brain scans showed reduced electrical activity across all frequency bands and increased neural complexity

• Changes in visual attention correlated with altered brainwave patterns, particularly in delta frequencies

🎯 New scale measures trauma memory processing during psychedelic therapy

• Researchers developed the "Helioscope Questionnaire" to measure how psychedelics like psilocybin and MDMA allow people to revisit traumatic memories without re-experiencing trauma symptoms

• The scale addresses a gap in existing assessment tools, which don't capture this unique "protected revisiting" effect

• This mechanism may be key to understanding how psychedelic therapy works for PTSD and trauma-related conditions

🍄 Psilocybin shows promise for binge eating disorder

• All 5 participants in a pilot study showed sustained reductions in binge eating episodes through 14 weeks after a single 25 mg psilocybin dose

• Depression and anxiety scores improved, and 3 participants lost weight (reduced BMI and waist circumference)

• Brain scans revealed increased activation in areas involved in food processing, including the middle frontal gyrus and angular gyrus

⚖️ WHO database reveals real-world psychedelic safety patterns

• Analysis of 2,056 adverse event reports found MDMA (1,573 reports) and LSD (394 reports) had the most safety reports globally

• Psychiatric events like substance abuse were most common, while overdose reports were rare (1.1-1.7% of total events)

• Pregnancy-related complications were uncommon, though both substances showed higher odds of substance use disorder reports compared to acetaminophen

💊 Low-dose psilocybin targets metabolic disorders through liver receptors

• Mice given 0.05 mg/kg psilocybin daily for 12 weeks showed reduced weight gain, liver fat, blood sugar, and insulin resistance without psychedelic effects

• The benefits worked through 5-HT2B receptors in the liver, not the 5-HT2A receptors responsible for hallucinations

• Multi-omics analysis revealed near-complete normalization of disrupted liver metabolism pathways